Clinical Trials · NCT06118008
A Study of HS-20094 in T2DM Participants
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrollment
- 54
- Start date
- May 2023
- Locations
- 1 site, China
- Primary endpoint
- Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug